Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Up 16.2% in November

Caribou Biosciences, Inc. (NASDAQ:CRBU) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 8,620,000 shares, an increase of 16.2% from the November 15th total of 7,420,000 shares. Approximately 10.9% of the company’s stock are short sold. Based on an average daily trading volume, of 1,280,000 shares, the days-to-cover ratio is presently 6.7 days.

Institutional Investors Weigh In On Caribou Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC lifted its position in Caribou Biosciences by 122.4% during the third quarter. Barclays PLC now owns 129,839 shares of the company’s stock valued at $255,000 after purchasing an additional 71,463 shares during the period. Geode Capital Management LLC lifted its position in Caribou Biosciences by 6.5% during the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after purchasing an additional 124,782 shares during the period. Erste Asset Management GmbH acquired a new position in Caribou Biosciences during the third quarter valued at $28,000. PFM Health Sciences LP lifted its position in Caribou Biosciences by 5.5% during the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after purchasing an additional 223,299 shares during the period. Finally, Walleye Capital LLC lifted its position in Caribou Biosciences by 45.9% during the third quarter. Walleye Capital LLC now owns 237,599 shares of the company’s stock valued at $466,000 after purchasing an additional 74,799 shares during the period. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CRBU has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a report on Friday, November 15th. Citigroup lowered their target price on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. Four equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $10.20.

Caribou Biosciences Stock Performance

CRBU traded down $0.02 during trading on Monday, hitting $1.89. The stock had a trading volume of 752,481 shares, compared to its average volume of 1,696,935. The company has a market capitalization of $171.15 million, a PE ratio of -1.16 and a beta of 2.27. Caribou Biosciences has a twelve month low of $1.50 and a twelve month high of $8.33. The stock has a 50 day simple moving average of $2.09 and a two-hundred day simple moving average of $2.04.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The business had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million. On average, equities research analysts anticipate that Caribou Biosciences will post -1.64 EPS for the current year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.